746
ANTIVIRAL THERAPY IMPROVES LONG-TERM HEALTH
RELATED QUALITY OF LIFE IN COMPENSATED HBV-CIRRHOSIS
PATIENTS
Xiaoning Wu1,2, Jia Hong1,2, Jialing Zhou2, Yameng Sun1,2,
Huiguo Ding3, Wen Xie4, Hongxin Piao5, Xiaoyuan Xu6, Wei
Jiang7, Bo Feng8, Mingyi Xu9, Jilin Cheng10, Xiaojuan Ou2,
Jidong Jia2 and Hong You11, (1)Beijing Friendship Hospital,
Capital Medical University, (2)Liver Research Center, Beijing
Friendship Hospital, Capital Medical University, Beijing Key
Laboratory of Translational Medicine in Liver Cirrhosis, National
Clinical Research Center of Digestive Diseases, Beijing,
China, (3)Department of Gastroenterology and Hepatology,
Beijing You’an Hospital, Capital Medical University, (4)Center
of Liver Diseases, Beijing Ditan Hospital, Capital Medical
University, (5)Infectious Department, Affiliated Hospital of
Yanbian University, Yanji, Jilin, China, (6)Peking University
First Hospital, (7)Department of Gastroenterology, Zhongshan
Hospital, Fudan University, Shanghai, China, (8)Hepatology
Institute, Peking University People’s Hospital, Beijing, China,
(9)Shanghai General Hospital, Shanghai Jiaotong University
School of Medicine, (10)Department of Gastroenterology,
Shanghai Public Health Clinical Center, Fudan University,
Shanghai, China, (11)Liver Research Center
Background: In patients with chronic hepatitis B virus (HBV)
infection, health-related quality of life (HRQOL) deteriorates
with disease progression Patients with compensated HBVcirrhosis
are at high risk of disease progression Antiviral
therapy can reverse some HBV-cirrhosis or reduce risk of
disease progression However, long-term change of HRQOL
in compensated HBV-cirrhosis on-treatment is unknown
Methods: Patients clinically diagnosed as compensated
HBV-cirrhosis were included and initiated entecavir (ETV)
therapy Five years data was collected at baseline and yearly
in clinical, biochemical, virological and imaging assessment
HRQOL was measured by European Quality of Life-5
Dimensions (EQ-5D) and Short Form-36 (SF-36) Logistic
regression was used to evaluate associate factors of HRQOL
improvement Results: A total of 571 patients were enrolled
with median age of 47 (40, 54) years old About 75 1%
patients were male gender and 44 8% were HBeAg positive
During 4 9 (2, 5 9) years of follow-up, sixty-four patients were
censored due to decompensation (n=28) or hepatocellular
carcinoma (n=36) In EQ5D, visual analogue scale (VAS)
score and utility index (UI) increased significantly (VAS:
79 6±16 8 to 85 0±16 8, UI: 0 89±0 11 to 0 92±0 08, both
P<0 001) 5 years on-treatment In SF-36, all eight dimensions
scores increased significantly with physical functioning
(88 4±15 7 to 92 0±10 3, P<0 001), physical role (63 2±40 7
to 72 3±39 9, P<0 001), bodily pain (79 8±19 0 to 84 2±16 8,
P<0 001), general health (53 8±20 6 to 63 9±21 7, P<0 001),
vitality (67 3±19 4 to 74 4±18 4, P<0 001), social functioning
(76 8±20 5 to 82 7±20 1, P<0 001), role emotional (64 4±41 5
to 74 9±38 2, P<0 001), and mental health (65 5±18 2 to
74 8±17 5, P<0 001) Physical component summary (PCS)
and mental component summary (MCS) were derived from
the above eight dimensions in SF-36 Both PCS and MCS
increased significantly 5 years on-treatment (PCS, 47.7±9.8
to 50 8±8 7; MCS, 46 2±11 0 to 50 8±10 4, both P<0 001)
Furthermore, in multivariate analysis, total bilirubin decrease
is associated with PCS improvement and female gender is
associated with MCS improvement at year-five. Conclusion:
Five-year antiviral treatment significantly improves health
related quality of life measured by EQ-5D and SF-36 in
patients with compensated HBV-cirrhosis.作者: StephenW 时间: 2020-10-24 14:05